title: Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required?
authors.affiliation: London.
authors.forename: Veronica
authors.initials: V
authors.lastname: Melchionda
authors.forename: Harry
authors.initials: H
authors.lastname: Wyatt
authors.forename: Santino
authors.initials: S
authors.lastname: Capocci
authors.forename: Raul
authors.initials: R
authors.lastname: Garcia Medina
authors.forename: Angelita
authors.initials: A
authors.lastname: Solamalai
authors.forename: Sotira
authors.initials: S
authors.lastname: Katiri
authors.forename: Susan
authors.initials: S
authors.lastname: Hopkins
authors.forename: Ian
authors.initials: I
authors.lastname: Cropley
authors.forename: Marc
authors.initials: M
authors.lastname: Lipman
mesh_terms: D000328:Adult; D000583:Amikacin / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use*; D001298:Audiology; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D034381:Hearing Loss / Q000139:chemically induced; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D012189:Retrospective Studies; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D000583:Amikacin